Trevarx Biomedical Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Series A
  • (In Progress)

  • Latest Deal Amount
  • $35M

  • Investors
  • 4

Trevarx Biomedical General Information

Description

Developer of novel small-molecule radiopharmaceutical platforms designed to provide an oncology paradigm that identifies and cures cancer. The company offers small-molecule PARP inhibitor analogues paired with diagnostic biomarkers and cytotoxic radioactive payloads, enabling oncology researchers and clinicians to detect tumor expression levels and deliver precision treatment in cancers such as neuroblastoma and ovarian cancer.

Contact Information

Website
www.trevarx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2929 Arch Street
  • Floor 3
  • Philadelphia, PA 19104
  • United States
+1 (206)
Primary Industry
Drug Delivery
Vertical(s)
Corporate Office
  • 2929 Arch Street
  • Floor 3
  • Philadelphia, PA 19104
  • United States
+1 (206)

Trevarx Biomedical Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Trevarx Biomedical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series A) 24-Oct-2025 $35M In Progress Clinical Trials - Phase 2
9. Mezzanine 04-Aug-2025 Completed Clinical Trials - Phase 2
8. Accelerator/Incubator 01-Jan-2025 Completed Clinical Trials - Phase 2
7. Grant 01-Sep-2023 Completed Clinical Trials - Phase 2
6. Grant Completed Clinical Trials - Phase 2
5. Later Stage VC 20-Sep-2022 Completed Clinical Trials - Phase 2
4. Grant 31-Mar-2022 Completed Startup
3. Grant 01-Mar-2021 Completed Startup
2. Seed Round 02-Aug-2019 $650K $650K Completed Startup
1. University Spin-Out 15-Aug-2016 Completed Startup
To view Trevarx Biomedical’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Trevarx Biomedical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Trevarx Biomedical Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
HiveBio Accelerator/Incubator
NASA SBIR/STTR Government
National Institutes of Health Government
University of Pennsylvania University
To view Trevarx Biomedical’s complete investors history, request access »

Trevarx Biomedical FAQs

  • When was Trevarx Biomedical founded?

    Trevarx Biomedical was founded in 2016.

  • Where is Trevarx Biomedical headquartered?

    Trevarx Biomedical is headquartered in Philadelphia, PA.

  • What is the size of Trevarx Biomedical?

    Trevarx Biomedical has 3 total employees.

  • What industry is Trevarx Biomedical in?

    Trevarx Biomedical’s primary industry is Drug Delivery.

  • Is Trevarx Biomedical a private or public company?

    Trevarx Biomedical is a Private company.

  • What is Trevarx Biomedical’s current revenue?

    The current revenue for Trevarx Biomedical is .

  • How much funding has Trevarx Biomedical raised over time?

    Trevarx Biomedical has raised $1.5M.

  • Who are Trevarx Biomedical’s investors?

    HiveBio, NASA SBIR/STTR, National Institutes of Health, and University of Pennsylvania have invested in Trevarx Biomedical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process